Regeneron Pharmaceuticals (REGN)

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the treatment of obesity.

US stocks ended May cautiously after strong monthly gains, as renewed trade tensions with China stirred market uncertainty.

11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD). 

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Jefferies upgraded Unity’s stock to ‘Buy’ from ‘Hold’ with a price target hike to $29 from $22.

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Pre-market stock analysis of S&P500 stocks on 2025-05-30: top gainers and losers in today's session.

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.